There is still some way to go, therefore, before what the individual patient needs (ie, an accurate prediction of future reproductive function and lifespan) can be provided, but this paper provides a significant advance in the use of AMH as a valuable biomarker in the field of postcancer ovarian function and, by broader implication, in women’s long-term health after cancer. Here, AMH is linked to cancer.